Feline Immunodeficiency Virus (FIV): Virology, Diagnosis & Management

Maigan Espinili Maruquin

1. Introduction: The Scientific and Clinical Significance of FIV

1.1 Historical Discovery of FIV (1986) and Its Relevance as an HIV Model

Feline Immunodeficiency Virus (FIV) was first recognized in 1986, when domestic cats in California presented with severe immunodeficiency syndromes remarkably similar to human AIDS. In 1987, Pedersen, Ho, and colleagues successfully isolated the virus, identifying it as a novel feline lentivirus and establishing the foundation for a new model of lentiviral immunopathogenesis (Pedersen, Ho et al. 1987).

Initial observations emphasized that affected cats showed clinical signs of profound immune dysfunction—fever, lymphadenopathy, recurrent infections—but were negative for Feline Leukemia Virus (FeLV), differentiating this syndrome from previously known retroviral diseases in cats (Harbour, D.A. et al. 2004).

Because FIV belongs to the Lentivirus genus within Retroviridae, similar to Human Immunodeficiency Virus (HIV), it was subsequently named in parallel with HIV. The biological, genomic, and pathological similarities between FIV and HIV—including their shared tropism for CD4⁺ T lymphocytes, slow progression, and lifelong persistence—positioned FIV early on as an important natural animal model for studying human AIDS (Elder & Phillips 1995; Miller, Cairns et al. 2000; Troyer, Pecon-Slattery et al. 2005; Hosie, Techakriengkrai et al. 2017).

To this day, FIV remains a critical comparative model for HIV vaccine development, antiviral therapy research, and studies of lentiviral immune dysfunction.

1.2 Classification as a Lentivirus and Early Pathogenesis Studies

FIV is a member of the Lentivirus genus, characterized by chronic, progressive infections and slow viral replication cycles. Like HIV, FIV integrates its genome into the host’s DNA to form a provirus, resulting in lifelong infection (Bendinelli, Pistello et al. 1995; Westman, Malik et al. 2019).

Three Major Clinical Stages of Infection

FIV infection progresses through a series of well-defined clinical stages that mirror HIV pathogenesis:

Acute (Primary) Infection

Occurs 1–6 weeks post-exposure and may last 1–4 weeks.

Common findings include:
• transient fever, lethargy, dullness
• generalized lymphadenopathy
• transient neutropenia
• anorexia, diarrhea
• mild upper respiratory signs
(Ishida & Tomoda 1990; Bendinelli, Pistello et al. 1995)

During this phase, the thymus and lymphoid tissues are important early replication sites where lesions may appear within 4 weeks (Harbour, D.A. et al. 2004).

Asymptomatic (Latent) Phase

Often lasts 1.5–2 years or longer.
• Cats appear healthy but remain persistently infected.
• Viral replication continues at low levels.
• Subclinical chronic inflammatory lesions may occur (Harbour, D.A. et al. 2004).

Terminal Immunodeficiency Phase (Feline AIDS; FAIDS)

Characterized by:
• severe immune collapse
• high viral replication
• chronic secondary infections
• neoplasia (especially lymphomas)
• neurological abnormalities
(Pedersen 1993; Bendinelli, Pistello et al. 1995; Westman, Malik et al. 2019)

These stages reflect lentiviral dynamics nearly identical to HIV progression in humans.

1.3 Distinction Between FIV and FeLV in Naturally Infected Cats

Although both FIV and FeLV are important feline retroviruses, they differ significantly in classification, transmission, and pathogenesis:

Classification and Molecular Differences

FIV: Lentivirus; elongated morphology; Mg²⁺-dependent reverse transcriptase (Harbour, D.A. et al. 2004).
FeLV: Gammaretrovirus; Mn²⁺-dependent reverse transcriptase.

Transmission

FIV: Primarily transmitted via bite wounds during fighting or mating aggression (Perharic, Bidin et al. 2016; Miller, Boegler et al. 2017).
FeLV: Transmitted via casual contact: grooming, shared bowls, and vertical passage.

Clinical Outcome

FIV:
• Lifelong persistent infection
• Slow immunodeficiency progression
• Many cats live normal or near-normal lifespans with appropriate care
FeLV:
• More acutely pathogenic
• Causes immunosuppression, anemia, lymphoma
• Can manifest as abortive, regressive, or progressive infection

These differences require distinct diagnostic and management approaches.

1.4 Why FIV Remains a Critical Feline Pathogen in Modern Veterinary Medicine

Global Prevalence and Risk Factors

FIV prevalence varies with geography, lifestyle, and demographics:
• 2.5–5 percent among healthy cats in North America
• Up to ≥15 percent in high-risk populations (Bendinelli, Pistello et al. 1995)
• Higher in older, free-roaming, intact male cats due to aggressive behaviors

Pathogenesis: Progressive Immune Dysfunction

FIV induces a chronic decline in immune function via:
• depletion of CD4⁺ T cells
• inversion of the CD4:CD8 ratio
• chronic immune activation
• susceptibility to secondary infections

These immune abnormalities closely mirror HIV-induce immunopathology.

Neoplastic and Neurological Sequelae

FIV markedly increases the risk of neoplasia, especially B-cell lymphosarcoma.
Neurological manifestations include:
• seizures
• altered behavior
• dementia
• ataxia
(Ishida & Tomoda 1990; Bendinelli, Pistello et al. 1995)

Transmission Challenges

Although FIV is shed in saliva, deep bite wounds remain the dominant transmission route. Viral RNA, DNA, and antibodies have been detected in saliva and oral tissues (Yamamoto, Sparger et al. 1988; Pedersen, Yamamoto et al. 1989; Miller, Boegler et al. 2017).

Ethical and Clinical Implications

Because many FIV-positive cats remain healthy for years:
• A positive test result must never be the sole basis for euthanasia (Harbour, D.A. et al. 2004).
• Appropriate counseling is required to prevent mismanagement.
• Early diagnosis enables interventions that improve longevity and quality of life.

Importance in HIV Research

The strong biological parallels between FIV and HIV continue to position FIV as a unique model for:
• immune dysfunction
• neurological disease
• vaccine development
• antiretroviral therapy testing
(Hosie, Techakriengkrai et al. 2017)

2. Virology and Molecular Biology

2.1 Viral Structure

Feline Immunodeficiency Virus (FIV) is a member of the Lentivirus genus within the Retroviridae family. Mature virions measure approximately 100–110 nm in diameter and contain a characteristic cylindrical nucleocapsid core. The virion is enclosed by a host-derived lipid bilayer acquired during budding from the plasma membrane of infected cells. Embedded within this lipid envelope are short surface glycoprotein spikes that are fundamental to viral infectivity and immune recognition.

The viral Env glycoprotein precursor undergoes proteolytic cleavage to produce two mature subunits:

Surface unit (SU, gp95)
Transmembrane unit (TM, gp40)

These subunits are non-covalently associated in a trimeric structure within the viral membrane. Together, they mediate:

Receptor recognition and binding
Membrane fusion and viral entry
Immune evasion and antigenicity, serving as major targets for neutralizing antibodies

The gp40 transmembrane glycoprotein is a key antigen detected by many point-of-care diagnostic kits, underscoring its immunological relevance.

Within the core, the virion contains two identical positive-sense RNA strands assembled with nucleocapsid proteins, essential viral enzymes, and structural components. This genome–nucleoprotein complex is enclosed by the capsid protein (CA, p24), itself surrounded by the matrix protein (MA, p14) that lines the inner surface of the envelope.

2.2 Genome Organization and Replication Cycle

Genome Organization

The FIV genome is approximately 9.4 kb in length and contains three canonical retroviral open reading frames (gag, pol, env) flanked by long terminal repeats (LTRs).

The gag gene encodes the Gag polyprotein, subsequently cleaved into structural proteins: MA (p14), CA (p24), and NC.
The pol gene encodes the Pol polyprotein, which contains four essential enzymes:
- Protease (PR)
- Reverse transcriptase (RT)
- Integrase (IN)
- dUTPase (DU), a feature not found in HIV
The env gene encodes the Env precursor, cleaved into SU (gp95) and TM (gp40) glycoproteins.

In addition to the major structural genes, FIV encodes several accessory and regulatory proteins, including:

rev – regulates mRNA export and expression of structural proteins
vif – counteracts host restriction factors
orfA (Orf2) – unique to FIV; enhances viral gene expression

These accessory elements contribute to viral persistence and tissue tropism.

Replication Cycle

The replication cycle of FIV mirrors that of other lentiviruses and proceeds through the following steps:

Attachment and Entry
Infection begins with the binding of SU (gp95) to the primary receptor CD134 (OX40) on CD4⁺ T lymphocytes and monocyte/macrophage lineages. This binding induces conformational changes exposing a site required for interaction with the co-receptor CXCR4. Subsequent structural rearrangements activate TM (gp40), enabling membrane fusion and viral entry.
Uncoating and Reverse Transcription
After penetration, the capsid disassembles and the viral reverse transcriptase synthesizes a double-stranded cDNA copy of the RNA genome. FIV reverse transcriptase is Mg²⁺-dependent, in contrast to the Mn²⁺-dependent reverse transcriptase of FeLV.
Proviral Integration
Viral integrase inserts the cDNA into the host genome, forming a provirus. Integration is essential for establishing lifelong infection and for subsequent gene expression.
Transcription, Translation, and Assembly
Upon cell activation, the integrated provirus is transcribed into viral RNA and mRNAs. The Rev protein facilitates nuclear export of unspliced and partially spliced transcripts. Assembly of structural proteins at the plasma membrane results in budding of immature virions.
Maturation
Viral protease cleaves the Gag and Pol polyproteins to form the mature capsid and enzyme complexes, yielding fully infectious virions.

This multi-step cycle underlies FIV’s ability to persist, evade immune responses, and establish chronic infection.

2.3 FIV Subtypes (A–E) and Global Distribution

FIV strains are genetically diverse, classified primarily by sequence variation in the V3–V5 region of the env gene. At least six major clades (A–F) have been described, along with a seventh clade (U-NZenv) unique to New Zealand.

Key features of subtype distribution:

Subtypes A and B are globally widespread.
Subtype A predominates in Australia.
Subtypes A and C are common in New Zealand.
Subtype D occurs mainly in Japan and Vietnam.
Subtype C has been associated with more severe clinical signs, including lymphopenia and neutropenia.
Recombinant subtypes (e.g., A/B, A/C) circulate in multiple regions.

This genetic diversity presents challenges for diagnostics, molecular surveillance, and vaccine development, particularly regarding cross-clade immune protection.

2.4 Comparison to HIV: Shared Molecular Mechanisms but Distinct Host Specificity

FIV shares many structural, genomic, and pathological features with HIV, reinforcing its value as an animal model for lentiviral biology.

Shared Molecular and Pathological Features	Distinct Mechanisms and Host Specificity
Both are lentiviruses within Retroviridae.	Species restriction: FIV infects felines; HIV infects humans and non-human primates.
Similar genomic organization (LTRs, gag, pol, env).	Primary receptor: FIV uses CD134; HIV uses CD4.
Both encode PR, RT, and IN.	Accessory genes differ: HIV has vpr, vpu, nef; FIV has orfA and lacks these HIV-specific genes.
Chronic infection with stages: acute, asymptomatic, terminal.	Co-receptors: Both use CXCR4, but HIV commonly uses CCR5, which FIV does not.
Progressive loss of CD4⁺ T-cells and immune dysfunction.	Pol gene differences: FIV encodes dUTPase, absent in HIV.
Neurological and immunodeficiency-related disease.	Reverse transcriptase cofactor requirements differ (Mg²⁺ for FIV and HIV; Mn^{2+ d}for FeLV).

Despite these distinctions, the close molecular parallel between FIV and HIV continues to provide critical insights into lentiviral replication, pathogenesis, and therapeutic strategies.

3. Pathogenesis and Disease Progression

3.1 Overview of FIV as a Lentivirus With Lifelong Persistence

Feline Immunodeficiency Virus (FIV) belongs to the Lentivirus genus within the Retroviridae family, a group of viruses characterized by chronic, progressive infections. Like other lentiviruses, FIV establishes a lifelong infection once it integrates its proviral DNA into the host genome. This integration is irreversible and central to the persistence of viral replication and immunologic decline.

As with Human Immunodeficiency Virus (HIV), persistent FIV infection leads to a progressive immunodeficiency syndrome involving T-lymphocyte dysfunction, chronic immune activation, and susceptibility to opportunistic infections, neurological disorders, and neoplastic disease.

3.2 Staged Clinical Progression

The clinical course of FIV infection is classically divided into three major sequential stages:

Acute (Primary) Infection
Asymptomatic (Latent) Phase
Terminal Immunodeficiency Phase, often termed Feline AIDS (FAIDS)

Disease expression varies widely between individuals due to differences in viral strain, host immune factors, age, lifestyle, and co-infections.

3.2.1 Acute Phase (Primary Infection)

The acute phase typically occurs 3–6 weeks post-infection and lasts from several weeks to months.

Clinical Features and Virologic Events

A short-lived viremic episode, detectable by PCR or virus isolation.
Transient clinical illness lasting 1–4 weeks, often mild or unnoticed by owners.
Signs may include:
- Fever (pyrexia)
- Lethargy, dullness, depression
- Generalized lymphadenopathy
- Anorexia, diarrhea
- Transient neutropenia
- Upper respiratory signs, stomatitis, dermatitis, conjunctivitis

Early lymphoid and thymic involvement
Following entry through bite wounds, the virus traffics to regional lymph nodes and lymphoid tissues where it replicates primarily in activated T-lymphocytes. Experimental studies indicate that the thymus becomes a site of intense viral replication, with detectable lesions emerging by approximately four weeks post-infection.

This stage closely parallels the primary HIV infection in humans, where acute viral expansion precedes immune containment.

3.2.2 Asymptomatic Phase

After the acute phase, cats enter a prolonged asymptomatic period, often lasting years, during which they may appear clinically normal.

Key Features

Persistent but low-level viral replication.
Gradual deterioration of immune function despite absence of overt clinical signs.
Increased susceptibility to chronic or recurrent infections.
Occasional chronic inflammatory lesions, including mild intestinal inflammation.
Latency of virus within peripheral CD4⁺ T-cells.

Most FIV-infected cats spend the majority of their lifespan in this stage, particularly when well-managed.

3.2.3 Persistent Generalized Lymphadenopathy (PGL)

PGL is regarded as an early symptomatic phase in both HIV and FIV infections.

Characteristics of PGL in FIV

Generalized, persistent enlargement of lymph nodes.
Accompanied by systemic signs such as:
- Recurrent fever
- Anorexia
- Mild to moderate weight loss
- Non-specific behavioral or activity changes

PGL may be brief or may coincide with the emergence of other opportunistic or inflammatory disorders.

3.2.4 AIDS-Related Complex (ARC)

The AIDS-Related Complex represents a transitional stage before terminal disease.

Clinical Characteristics

Chronic secondary infections, commonly affecting:
- Oral cavity (stomatitis, gingivitis)
- Skin
- Upper respiratory tract
Systemic signs include:
- Weight loss (without severe emaciation)
- Persistent fever
- Lymphadenopathy
- Gastrointestinal disease
- Hematologic abnormalities

These signs reflect early immune failure and resemble the pre-AIDS manifestations in HIV-infected individuals. ARC usually progresses to FAIDS.

3.2.5 Feline AIDS (FAIDS)

FAIDS represents the terminal stage of FIV infection, characterized by severe immune dysfunction and high viral replication.

Key Features

Opportunistic infections that are often treatment-resistant and rapidly progressive.
Marked systemic deterioration, leading to poor clinical outcomes.
Neoplasia, most notably:
- Malignant lymphoma, particularly B-cell lymphomas
- Fibrosarcoma
- Mast cell tumor
- Leukemia
- Squamous cell carcinoma
  FIV-infected cats are reported to be five times more likely to develop tumors than uninfected cats.

Neurological manifestations may include:

Altered behavior or cognitive decline
Seizures
Ataxia, nystagmus
Intention tremors
Stereotypic motor behaviors (e.g., compulsive roaming)
Impaired motor and sensory function

Neurologic disease is recognized as a significant component of late-stage FIV pathology, reflecting the virus’s ability to infect the central nervous system.

3.3 Hematologic Abnormalities

FIV induces progressive hematologic and immunologic impairment:

CD4⁺ T-cell depletion: The hallmark abnormality. A progressive decline in CD4⁺ T-cells leads to inversion of the CD4:CD8 ratio, often maintained throughout life.
Neutropenia: Frequently observed, particularly in experimental infections where FIV-positive cats remain neutropenic across multiple timepoints.
Anemia: Progressive, non-regenerative anemia is common in advanced disease.
Other abnormalities: Leukopenia, lymphopenia, thrombocytopenia, and bone marrow suppression may occur as disease progresses.

These hematologic patterns mirror those seen in human AIDS, highlighting the depth of immune disruption.

3.4 Histopathology

Histopathological findings parallel the clinical stages of FIV infection.

Lymphoid Tissues

Follicular hyperplasia during early infection and PGL.
Transition to follicular depletion, involution, and architectural collapse as FAIDS develops.
Splenic lesions resembling those in lymph nodes.

Thymus

Thymic atrophy, especially notable in acute infection due to early viral replication.

Non-Lymphoid Tissues

Oral cavity: Mild to proliferative gingivitis and periodontitis, often associated with secondary infections.
Kidneys:
- Glomerulonephritis
- Proteinuria
- Tubular microcysts
- Interstitial inflammatory infiltrates
- Glomerular and interstitial amyloidosis, particularly in naturally infected cats in advanced stages

These changes reinforce the systemic impact of FIV and the virus’s ability to disrupt both immune and non-immune organ systems.

4. Epidemiology and Transmission

Feline Immunodeficiency Virus (FIV) is a globally distributed lentivirus recognized as a significant pathogen of domestic cats. Prevalence varies widely by region and population demographics. In North America, 2.5–5 percent of healthy cats are infected, whereas prevalence increases to 15 percent or more in sick, free-roaming, or high-risk cats. Similar trends are reported worldwide, particularly in populations with substantial outdoor access or high rates of intercat aggression.

4.1 Primary Transmission: Biting During Agonistic Encounters

The primary mode of FIV transmission is horizontal spread through bite wounds, which introduce FIV-infected leukocytes and virus-rich saliva deep into tissues. Because transmission is driven largely by fighting behavior, infection risk is strongly influenced by sex, lifestyle, and territoriality.

Key points:

Free-roaming, intact male cats exhibit the highest infection rates due to their increased involvement in territorial aggression.
Casual, non-aggressive contact—including mutual grooming, shared bedding, or shared feeding/litter areas—is not an efficient route of transmission.
Household spread among stable, non-fighting cats is rare.
Although FIV can be shed in semen, sexual transmission is considered uncommon in natural settings.

This transmission pattern helps explain the demographic skew toward older, outdoor-access male cats.

4.2 Vertical Transmission via Colostrum and Milk

Vertical transmission of FIV from an infected queen to her kittens has been demonstrated experimentally, occurring via:

In utero transmission
Postnatal exposure through colostrum or milk

However, natural vertical transmission appears uncommon or rare, likely due to relatively low viral loads in queens with chronic infection. The risk increases when:

A queen is acutely infected during pregnancy, or
A queen is severely immunocompromised at the time of nursing.

Understanding these subtleties is important for managing breeding queens and evaluating FIV-positive pregnant cats.

4.3 Viral Excretion Mechanisms

FIV is shed in high concentrations in saliva, particularly during early infection. Viral replication within the ductal epithelial cells of the salivary glands contributes to this high salivary viral burden.

Excretion-related observations include:

Detection of viral RNA, proviral DNA, and FIV-specific antibodies in saliva.
The presence of immunoglobulin G (IgG) derived from gingival crevicular fluid offers the possibility of saliva-based antibody testing, although use of saliva in point-of-care tests is considered off-label due to variable sensitivity.

Despite high salivary viral load, transmission requires deep tissue inoculation, which explains why casual contact does not efficiently spread FIV.

4.4 Risk Factors: Age, Sex, Geographic Distribution

Several demographic and environmental factors significantly influence FIV prevalence:

Sex

Male cats are approximately four times more likely to test positive for FIV than females.
This disparity reflects a behavioral difference—males, especially intact outdoor-access males, engage more frequently in territorial fighting.

Age

Prevalence increases with age, as FIV includes a long asymptomatic period.
Adult cats (3.3–4.1 percent) exhibit significantly higher infection rates than juveniles (1.0–1.4 percent).

Lifestyle

Outdoor access is one of the strongest predictors of infection.
- One study reported a 4.3 percent prevalence in outdoor-access cats compared with 0.9 percent in strictly indoor cats.
Cats presenting with bite wounds, abscesses, or chronic oral inflammation show markedly higher positivity rates.

Clinical Status

Sick cats (6.1–6.3 percent prevalence) are significantly more likely to be infected than healthy cats (1.8 percent).

Geographic Variation

FIV is globally distributed, but prevalence varies by region.
In Australia, prevalence reaches 15–16 percent in outdoor-access adult cats.

This epidemiological distribution reflects the behavior-driven nature of FIV transmission.

4.5 Why FIV Often Remains Undiagnosed

Despite its widespread nature, FIV frequently remains undetected in infected cats. Several factors contribute to underdiagnosis:

Long Incubation Period and Asymptomatic Carriage

FIV infection is characterized by a prolonged asymptomatic phase, often lasting 7.5–12.5 years, during which the cat appears clinically healthy. Because external signs are absent, infected cats may not be tested until late-stage disease emerges.

Nonspecific Early Signs

Clinical signs in the acute phase—fever, transient lymphadenopathy, mild depression—are typically:

Subtle
Short-lived
Easily overlooked or attributed to unrelated causes

By the time clinical disease becomes apparent, the virus may have been present for many years.

Analogy: The Silent Progression of FIV

FIV behaves much like a slow-burning fuse:

The initial spark (acute phase) is brief and often unnoticed.
The long, smoldering interval (asymptomatic phase) stretches across years, quietly altering the immune system.

The sudden flare (terminal phase) appears unexpectedly, revealing a process that has been unfolding silently for most of the cat’s life.

5. Clinical Manifestations of FIV

Feline Immunodeficiency Virus (FIV) causes a slow, progressive deterioration of immune function, leading to a broad spectrum of clinical signs. The disease course aligns closely with the stages described in lentiviral infections, with clinical manifestations reflecting a combination of direct viral effects and secondary complications of acquired immunodeficiency.

5.1 Signs Directly Attributable to Viral Activity

Clinical signs in FIV infection parallel the three major stages of disease progression.

Acute Phase (Primary Infection)

The acute stage develops 3–6 weeks post-infection and typically lasts 1–3 months. This stage may be entirely subclinical or characterized by a short, mild illness.

Common findings include:

Transient fever (pyrexia)
Peripheral lymphadenopathy (generalized lymph node enlargement)
Lethargy, malaise, depression
Transient neutropenia and lymphopenia
Occasionally: anorexia, diarrhea, stomatitis, conjunctivitis, dermatitis, or mild upper respiratory signs

During this phase, viremia is high, and the virus disseminates to lymphoid tissues—including the thymus—where early replication occurs.

Asymptomatic (Latent) Phase

Following the acute phase, cats may remain clinically normal for many months to years. Viral replication persists at low levels, but immune deterioration slowly progresses.

Key features:

Cats appear outwardly healthy
Gradual, ongoing decline in CD4⁺ T-cells
Occasional chronic inflammatory lesions (e.g., intestinal inflammation)
Viral latency in peripheral CD4⁺ lymphocytes

This phase represents the longest clinical stage for most infected cats.

Clinical/Terminal Immunodeficiency Phase (Secondary Disease / FAIDS)

As immune failure becomes pronounced, clinical signs intensify and persist.

Characteristic findings:

Generalized lymphadenopathy
Persistent fever
Progressive weight loss → severe wasting late in disease
Anemia, neutropenia, lymphopenia, thrombocytopenia
Hyperglobulinemia, reflecting chronic antigenic stimulation and immune dysregulation

The immunologic collapse predisposes cats to chronic infections, neoplasia, and neurological disease—similar to end-stage HIV infection in humans.

5.2 Secondary and Opportunistic Infections

As immunodeficiency progresses, FIV-infected cats become susceptible to a wide range of secondary and opportunistic infections. These conditions often dominate the clinical picture in late-stage disease.

Oral Cavity

Gingivostomatitis
- Most common syndrome in naturally infected cats
- Frequently severe, ulcerative, and refractory to treatment
- Often begins in the pharyngeal region and extends rostrally
Periodontitis

Respiratory Tract

Chronic rhinitis
Recurrent upper respiratory infections

Skin

Chronic dermatitis
Necrotizing or ulcerative lesions
Opportunistic etiologies such as mycobacteriosis, leishmaniasis, toxoplasmosis, and dermatophytosis

Urinary Tract

Chronic or recurrent cystitis

Gastrointestinal System

Chronic, persistent diarrhea

Eyes

Uveitis
Chorioretinitis
Other inflammatory ocular diseases

Common Opportunistic Pathogens

Toxoplasma gondii (toxoplasmosis)
Leishmania infantum
Mycoplasma haemofelis and Mycoplasma hemominutum (hemoplasmosis)
Cladosporium carrionii (chromoblastomycosis)

In one cohort of naturally infected cats:

48% had hemoplasmosis
23% had toxoplasmosis
14% had fungal infections

These statistics underscore the profound immune impairment associated with FIV.

5.3 Neurological Abnormalities

FIV is a neurotropic lentivirus, and neurological disorders constitute an important part of the disease spectrum. Up to 5 percent of clinically affected cats may present with neurological signs as their primary complaint, although microscopic CNS lesions are more common than overt clinical symptoms.

Behavioral and Cognitive Changes

Altered demeanor, anxiety, irritability
Compulsive roaming, disturbed sleep cycles
Cognitive decline (dementia), particularly in older cats
- Evidence suggests synergistic interaction between FIV and age-related cognitive impairment
- Significant impact on visuospatial working memory

Motor and Coordination Deficits

Ataxia
Intention tremors
Twitching of facial and lingual muscles
Gait abnormalities: increased stance width, slowed navigation, more maze errors in experimental models

Seizures and Ocular Signs

Seizures (convulsions)
Anisocoria, nystagmus, delayed pupillary reflexes

Autonomic Dysfunction

Urinary and fecal incontinence, occasionally observed

Neuropathology

Microscopic lesions commonly include:

Perivascular mononuclear infiltrates (nonsuppurative encephalitis)
Diffuse gliosis (microglial and astrocyte activation)
Neuronal degeneration and loss
Myelin degeneration, particularly in the caudate nucleus, midbrain, and rostral brainstem

These abnormalities reflect the ability of FIV to infect CNS macrophages (microglia) and infiltrating lymphocytes, gradually disrupting neurologic function.

5.4 Neoplastic Associations (Lymphoma and Lymphosarcoma)

FIV infection is linked with a significantly increased risk of neoplasia, particularly lymphoid cancers. Infected cats are estimated to be five to six times more likely to develop lymphoma or leukemia compared to uninfected cats.

Most Common Neoplasms

Malignant lymphoma (lymphosarcoma)
- Often high-grade B-cell origin
- Commonly affects the intestinal tract, abdominal lymph nodes, and kidneys

Mechanisms of Oncogenesis

The oncogenic effects of FIV appear to be indirect, arising from:

Impaired immune surveillance
Chronic B-cell activation and proliferation
Dysregulation of cytokines and lymphoid architecture

Direct oncogenic activation through proviral insertion is rare, unlike in FeLV infection.

Other Reported Tumors

Leukemia
Fibrosarcoma
Mast cell tumor
Cutaneous squamous cell carcinoma

Neoplastic disease typically emerges years after initial infection, highlighting the chronic immunopathology characteristic of FIV.

6. Diagnosis of FIV

The most important measure for controlling Feline Immunodeficiency Virus (FIV) infection is the accurate identification of infected cats, followed by appropriate segregation and long-term clinical management. The American Association of Feline Practitioners (AAFP) recommends that cats be tested:

When first acquired
After potential exposure to an FIV-infected cat
When presenting with clinical signs consistent with retroviral disease

Because FIV establishes a persistent, lifelong infection, detection of FIV-specific antibodies remains the primary method of screening.

6.1 Serologic Detection of Antibodies

Once infected, cats typically mount a strong and persistent humoral immune response. FIV-specific antibodies remain detectable for life and therefore serve as reliable markers of infection.

Interpretation in Kittens: Maternal Antibodies

Maternal antibodies (MDA) complicate interpretation of FIV tests in kittens:

Kittens nursing from naturally infected or vaccinated queens may test FIV antibody–positive up to 6 months of age.
Most antibody-positive kittens from FIV-infected or vaccinated queens serorevert as maternally derived antibodies wane.
In one study, kittens born to vaccinated, uninfected queens all tested antibody-positive initially but became negative by 12 weeks.

Testing recommendations for kittens:

Retest every 60 days until the kitten is ≥6 months old.
Kittens that remain antibody-positive beyond 6 months are likely infected.

PCR may be used earlier to clarify infection status in antibody-positive kittens.

6.2 Point-of-Care Rapid Tests

Rapid point-of-care (POC) tests are the most commonly used FIV screening tools in veterinary practice. These tests detect FIV antibodies using ELISA or rapid immunomigration (RIM) technology.

Example: Bioguard VETlabs FeLV Ag / FIV Ab Combo Test

This test simultaneously detects FeLV antigen and FIV antibodies using a lateral flow immunochromatographic assay:

The test strip includes a test (T) zone and control (C) zone.
If FIV antibodies are present, antigen–antibody complexes form a visible line at the T zone.
Can be used with whole blood, plasma, or serum.

Most POC tests are highly sensitive and specific for detecting natural FIV infection. Some assays detect antibodies targeting gp40, while others detect antibodies to p15 or p24.

However, POC tests typically cannot distinguish between antibodies from natural infection and those induced by vaccination.

6.3 Laboratory Diagnostics

Confirmatory or secondary testing is recommended when:

A positive POC result conflicts with the clinical picture
The cat is considered low risk

The result could lead to euthanasia or major management changes

6.3.1 ELISA

ELISA tests detect FIV-specific antibodies and are widely used both in-clinic and in laboratories.

Strengths:

High sensitivity and specificity in unvaccinated cats
Suitable for initial screening

Limitations:

False positives may occur in FIV-vaccinated cats
Occasional false negatives in early or advanced infection

6.3.2 Western Blot (WB)

Western blotting detects antibodies to individual viral proteins.

Utility:

Historically considered the gold standard for confirming positive screening tests
Recommended mainly for ambiguous or discordant cases

However, studies suggest that some modern POC tests may perform equally well or better.

6.3.3 Virus Isolation

Virus isolation involves culturing FIV from tissues or blood.

Highly specific
Not routinely used due to being expensive, time-consuming, and requiring specialized facilities

Primarily used in research settings

6.3.4 Detection of Reverse Transcriptase Activity

Reverse transcriptase assays can confirm the presence of retroviral replication in cultured samples but are not used routinely in clinical practice.

6.3.5 Immunohistochemistry (IHC)

IHC detects viral antigen within fixed tissue sections.

Useful for demonstrating local viral presence (e.g., lymph nodes)
Primarily used for research or in postmortem diagnostics

6.4 Molecular Diagnostics

Molecular assays detect viral nucleic acids, rather than host antibodies.

6.4.1 PCR for Proviral DNA

PCR amplifies sequences of integrated proviral DNA in infected cells.

Advantages:

Highly sensitive, capable of detecting low-level infection
Useful for confirming infection in:
- Vaccinated cats, where antibody-based tests may be confounded
- Early infection, before seroconversion
- Late infection, when antibodies may wane
- Cases with discordant serology

Limitation:
A negative PCR result does not completely rule out infection, especially during the asymptomatic stage when proviral load may be low.

6.4.2 Real-Time PCR (qPCR)

Real-time PCR offers:

Reduced contamination risk
Faster turnaround
Ability to quantify viral load, though viral load does not always correlate with clinical stage

6.4.3 In Situ Hybridization

Detects viral RNA (mRNA) in tissues using labeled probes.

Demonstrates active viral transcription
Used primarily for research and pathologic investigation

6.5 Summary Table: Diagnostic Methods, Sensitivity, and Clinical Application

Diagnostic Method	Target	Sample Type	Advantages / Limitations	Best Use
POC Tests	Antibodies	Whole blood, plasma, serum	High sensitivity/specificity; vaccine antibodies may cause false positives; false negatives in early/late infection	Initial screening
ELISA (Lab)	Antibodies	Serum, plasma	High accuracy; cannot differentiate vaccine vs natural infection	Routine screening
Western Blot	Antibodies to individual proteins	Serum, plasma	Confirms ambiguous results; labor-intensive	Confirmation of positive or discordant cases
PCR (Proviral DNA)	Integrated proviral DNA	Buffy coat, blood, tissue	High sensitivity; excellent for vaccinated cats; negative result does not always rule out infection	Confirmatory testing
Real-Time PCR	Viral load	Plasma, tissue	Quantitative; reduced contamination	Viral load assessment; advanced diagnostics
Virus Isolation	Live virus	Tissue or PBMC	Highly specific; costly and slow	Research only
IHC	Viral antigen in tissue	Fixed biopsy	Localizes viral protein	Research or postmortem
In Situ Hybridization	Viral mRNA in tissue	Fixed tissue	Detects active transcription	Research

10. Conclusion

10.1 Summary of Key Scientific Insights

Feline Immunodeficiency Virus (FIV) remains one of the most important retroviral pathogens of domestic cats. As a naturally occurring lentivirus infection that closely parallels human immunodeficiency virus (HIV), FIV continues to serve as a valuable model for understanding lentiviral pathogenesis, immune dysfunction, and therapeutic strategies.

Key scientific insights include:

Progressive Immunodeficiency:
FIV induces a characteristic progression of immune dysfunction. The hallmark abnormality is a progressive decline in CD4⁺ T-lymphocytes and subsequent inversion of the CD4:CD8 ratio, representing a central mechanism underlying susceptibility to opportunistic infections and chronic inflammatory disease.
Individual Variability in Clinical Outcome:
While FIV infection is associated with increased morbidity and mortality, many FIV-infected cats—particularly those maintained in stable environments—experience normal or near-normal longevity. Clinical outcome depends heavily on housing conditions, stress levels, secondary infections, and individual immune response.
Neurological and Neoplastic Sequelae:
FIV is a neurotropic lentivirus, capable of inducing cognitive decline, behavioral abnormalities, and motor dysfunction. Additionally, FIV significantly elevates the risk of neoplasia, especially malignant lymphoma of B-cell origin, likely through indirect mechanisms such as impaired immunosurveillance and chronic antigenic stimulation.
Lymphoid Tissue Reservoirs:
Despite the apparent clinical quiescence of the asymptomatic phase, active viral replication persists in lymphoid tissues, highlighting the presence of deep viral reservoirs and explaining ongoing immune perturbations even when peripheral blood viral loads appear low.

These insights underscore the biological complexity of FIV and its importance as a translational model for HIV/AIDS research.

10.2 Importance of Accurate Diagnostics and Clinical Monitoring

Modern FIV management relies heavily on accurate diagnosis, regular monitoring, and prudent clinical decision-making.

Accurate Diagnostics

Controlling Transmission:
Identifying and appropriately segregating infected cats constitutes the most effective population-level control strategy for both FIV and FeLV.
Preventing Misdiagnosis and Unnecessary Euthanasia:
Because false-positive antibody results can occur, especially in vaccinated cats, a positive POC test must be confirmed using an alternative method (PCR or a DIVA-capable antibody test). FIV infection status must never be the sole basis for euthanasia.
Addressing Vaccine Interference:
The persistence of vaccine-induced antibodies complicates interpretation of many POC assays. The use of Witness™ or Anigen Rapid™—tests validated to distinguish vaccinated from naturally infected cats—or nucleic acid testing (PCR) helps mitigate this challenge.

Clinical Monitoring

Early Intervention:
FIV-infected cats experience recurrent and chronic infections due to progressive immunosuppression. Biannual health checks facilitate early detection and timely treatment, improving quality of life and survival.
Holistic Prognostic Evaluation:
Knowledge of retrovirus status guides long-term health planning. Many FIV-positive cats achieve excellent longevity when managed proactively.
Focused Physical and Laboratory Monitoring:
Regular evaluation of the oral cavity, lymph nodes, eyes, skin, and immune status (CBC, serum biochemistry, urinalysis) allows clinicians to differentiate between FIV-related pathology and age-associated comorbidities, essential for informed decision-making.

10.3 Research Directions in Lentiviral Immunology and Feline Health

FIV continues to serve as a scientifically rich model for exploring lentiviral biology, improving diagnostic precision, and developing next-generation therapeutics.

FIV as a Model for HIV Research

Due to its parallel pathogenesis, FIV enables:

comparative immunology studies,
exploration of neurocognitive dysfunction,
development of antiviral strategies,
and elucidation of oral and systemic inflammatory mechanisms relevant to HIV.

Advancing Antiretroviral Therapy (ART)

There is a critical need for controlled clinical studies evaluating antiretroviral combinations specifically tailored to feline physiology. Promising avenues include:

dolutegravir-based regimens, which show favorable pharmacokinetics,
ART protocols designed to reduce viral rebound and improve mucosal immunity,
and drug combinations that balance efficacy with low toxicity and high genetic barriers to resistance.

Vaccine Development

Persistent challenges include the remarkable genetic diversity of FIV (subtypes, recombinants) and the risk of vaccine-induced enhancement.

Current areas of focus involve:

multi-epitope vaccine design targeting conserved proteins (Gag-p24, Pol-RT),
advanced adjuvant systems (AS01/AS03, MVA, DNA and mRNA platforms),
strategies to elicit potent T-cell immunity,
and optimization of vaccine responses across circulating FIV clades.

Next-Generation Diagnostics

Efforts are underway to integrate:

proviral load quantification,
RNA viral activity assays,
saliva- or micro-sample POC testing,
and biomarkers reflecting immune exhaustion or reservoir activity.

Such advancements support earlier detection, more accurate staging, and individualized clinical management.

Summary: The Role of Rapid Testing in FIV Management

Given the lifelong persistence of FIV infection and the stable presence of virus-specific antibodies in infected cats, rapid antibody-based point-of-care testing remains the most practical and clinically relevant approach for routine screening. In everyday veterinary practice, rapid tests enable early identification of infected cats during initial presentation, adoption screening, or after potential exposure, facilitating timely management and appropriate counseling. Products such as the Bioguard Corporation FeLV Ag / FIV Ab Combo Rapid Test provide reliable, in-clinic detection of FIV antibodies using whole blood, serum, or plasma, allowing veterinarians to make informed decisions without delay. When integrated into regular health assessments, rapid testing plays a critical role in reducing underdiagnosis, preventing inappropriate clinical decisions, and supporting long-term monitoring of FIV-positive cats, many of whom can maintain good quality of life with proper care.

Recommended Rapid Screening Tests and Clinical Rationale

Screening Category	Recommended Product	Clinical Rationale
FeLV / FIV Screening	Bioguard FeLV Ag / FIV Ab Combo Test	FeLV and FIV are strongly associated with immunosuppression, chronic inflammation, and lymphoma. Rapid screening enables early identification, reduces underdiagnosis, and supports appropriate long-term management.
Retrovirus Screening at First Presentation	Bioguard FeLV Ag / FIV Ab Combo Test	Recommended for newly adopted cats, outdoor-access cats, and cats with unknown medical history to guide housing, vaccination, and monitoring strategies.
Immunodeficiency Risk Assessment	Bioguard FeLV Ag / FIV Ab Combo Test	Useful in cats presenting with recurrent infections, chronic stomatitis, weight loss, or lymphadenopathy, where underlying retroviral infection must be ruled out.
Population-Level Disease Control	Bioguard FeLV Ag / FIV Ab Combo Test	Rapid in-clinic testing supports segregation and preventive strategies in multi-cat households, shelters, and breeding environments.

📩 How to Order
The FeLV Ag/ FIV Ab Combo Test listed above are available exclusively to licensed veterinarians and veterinary hospitals. To place an order or request a quotation, please contact our sales team or email our customer service:

📧 service@bioguardlabs.com
☎️ Please include your hospital name and contact number in the email so our sales representative can follow up with you directly.

References

Beebe, A. M., N. Dua, T. G. Faith, P. F. Moore, N. C. Pedersen and S. Dandekar (1994). “Primary stage of feline immunodeficiency virus infection: viral dissemination and cellular targets.” Journal of virology 68(5): 3080-3091.
Bendinelli, M., M. Pistello, S. Lombardi, A. Poli, C. Garzelli, D. Matteucci, L. Ceccherini-Nelli, G. Malvaldi and F. Tozzini (1995). “Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.” Clin Microbiol Rev 8(1): 87-112.
D.A. Harbour, S.M.A. Caney and A.H. Sparkes (2004). Feline Immunodeficiency Virus Infection. Feline Medicine and Therapeutics: 607-622.
Dua, N., G. Reubel, P. F. Moore, J. Higgins and N. C. Pedersen (1994). “An experimental study of primary feline immunodeficiency virus infection in cats and a historical comparison to acute simian and human immunodeficiency virus diseases.” Vet Immunol Immunopathol 43(4): 337-355.
Egberink, H. F., E. J. Keldermans, M. J. M. Koolen, and M. C. Horzinek. 1992. Humoral immune response to feline immunodeficiency virus in cats with experimentally induced and naturally acquired infections. Am. J. Vet. Res. 53:1133–1138.
Egberink, H. F., H. Lutz and M. C. Horzinek (1991). “Use of western blot and radioimmunoprecipitation for diagnosis of feline leukemia and feline immunodeficiency virus infections.” J Am Vet Med Assoc 199(10): 1339-1342.
Elder, J. H. and T. R. Phillips (1995). “Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections.” Adv Virus Res 45: 225-247.
Guiot, A. L., D. Rigal, D. Pialot and G. Chappuis (1995). “Development of a simple, rapid and accurate in vitro whole blood technique for the detection and semi-quantification of FIV cellular viremia.” Vet Microbiol 47(3-4): 331-342.
Hesselink, W., P. Sondermeijer, H. Pouwels, E. Verblakt and C. Dhore (1999). “Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge.” Vet Microbiol 69(1-2): 109-110.
Hohdatsu, T., S. Okada, K. Motokawa, C. Aizawa, J. K. Yamamoto and H. Koyama (1997). “Effect of dual-subtype vaccine against feline immunodeficiency virus infection.” Veterinary Microbiology 58(2): 155-165.
Hopper, C. D., A. H. Sparkes, T. J. Gruffydd-Jones, S. M. Crispin, P. Muir, D. A. Harbour and C. R. Stokes (1989). “Clinical and laboratory findings in cats infected with feline immunodeficiency virus.” Vet Rec 125(13): 341-346.
Hosie, M. J., J. N. Flynn, M. A. Rigby, C. Cannon, T. Dunsford, N. A. Mackay, D. Argyle, B. J. Willett, T. Miyazawa, D. E. Onions, O. Jarrett and J. C. Neil (1998). “DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.” J Virol 72(9): 7310-7319.
Hosie, M. J. and O. Jarrett (1990). “Serological responses of cats to feline immunodeficiency virus.” Aids 4(3): 215-220.
Hosie, M. J., N. Techakriengkrai, P. M. Beczkowski, M. Harris, N. Logan and B. J. Willett (2017). “The Comparative Value of Feline Virology Research: Can Findings from the Feline Lentiviral Vaccine Be Translated to Humans?” Vet Sci 4(1).
Ishida, T. and I. Tomoda (1990). “Clinical staging of feline immunodeficiency virus infection.” Nihon Juigaku Zasshi 52(3): 645-648.
Kakinuma, S., K. Motokawa, T. Hohdatsu, J. K. Yamamoto, H. Koyama and H. Hashimoto (1995). “Nucleotide sequence of feline immunodeficiency virus: classification of Japanese isolates into two subtypes which are distinct from non-Japanese subtypes.” Journal of virology 69(6): 3639-3646.
Lafrado, L. J., M. Podell, S. Krakowka, K. A. Hayes, M. A. Hanlon, and L. E. Mathes. 1993. FIV: a model for retrovirus-induced pathogenesis. AIDS Res. Rev. 3:115–150.
Lombardi, S., A. Poli, C. Massi, F. Abramo, L. Zaccaro, A. Bazzichi, G. Malvaldi, M. Bendinelli and C. Garzelli (1994). “Detection of feline immunodeficiency virus p24 antigen and p24-specific antibodies by monoclonal antibody-based assays.” J Virol Methods 46(3): 287-301.
Matsumura, S., T. Ishida, T. Washizu, I. Tomoda, S. Nagata, J. Chiba, and T. Kurata. 1993. Pathologic features of acquired immunodeficiency-like syndrome in cats experimentally infected with feline immunodeficiency virus. J. Vet. Med. Sci. 55:387–394
Matteucci, D., F. Baldinotti, P. Mazzetti, M. Pistello, P. Bandecchi, R. Ghilarducci, A. Poli, F. Tozzini and M. Bendinelli (1993). “Detection of feline immunodeficiency virus in saliva and plasma by cultivation and polymerase chain reaction.” Journal of clinical microbiology 31(3): 494-501.
Matteucci, D.; Poli, A.; Mazzetti, P.; Sozzi, S.; Bonci, F.; Isola, P.; Zaccaro, L.; Giannecchini, S.; Calandrella, M.; Pistello, M.; et al. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J. Virol. 2000, 74, 10911–10919.
Miller, C., K. Boegler, S. Carver, M. MacMillan, H. Bielefeldt-Ohmann and S. VandeWoude (2017). “Pathogenesis of oral FIV infection.” PLoS One 12(9): e0185138.
Miller, R. J., J. S. Cairns, S. Bridges and N. Sarver (2000). “Human Immunodeficiency Virus and AIDS: Insights from Animal Lentiviruses.” Journal of Virology 74(16): 7187-7195.
Miyazawa, T., K. Tomonaga, Y. Kawaguchi and T. Mikami (1994). “The genome of feline immunodeficiency virus.” Arch Virol 134(3-4): 221-234.
Pecoraro, M. R., K. Tomonaga, T. Miyazawa, Y. Kawaguchi, S. Sugita, Y. Tohya, C. Kai, M. E. Etcheverrigaray and T. Mikami (1996). “Genetic diversity of Argentine isolates of feline immunodeficiency virus.” J Gen Virol 77 ( Pt 9): 2031-2035.
Pedersen, N. C., E. W. Ho, M. L. Brown and J. K. Yamamoto (1987). “Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.” Science 235(4790): 790-793.
Pedersen, N. C. 1993. Feline immunodeficiency virus infection. In J. A. Levy (ed.), The retroviruses, vol. 2. Plenum Press, New York.
Pedersen, N. C., J. K. Yamamoto, T. Ishida and H. Hansen (1989). “Feline immunodeficiency virus infection.” Vet Immunol Immunopathol 21(1): 111-129.
Perharic, M., M. Bidin, V. Staresina, Z. Milas, N. Turk, Z. Stritof, S. Hadina, J. Habus, V. Stevanovic, V. Mojcec-Perko, S. Kovac, K. Martinkovic and L. Barbic (2016). “Phylogenetic characterisation of feline immunodeficiency virus in naturally infected cats in Croatia indicates additional heterogeneity of subtype B in Europe.” Arch Virol 161(9): 2567-2573.
Poli, A., C. Giannelli, M. Pistello, L. Zaccaro, D. Pieracci, M. Bendinelli and G. Malvaldi (1992). “Detection of salivary antibodies in cats infected with feline immunodeficiency virus.” Journal of clinical microbiology 30(8): 2038-2041.
Sodora, D. L., E. G. Shpaer, B. E. Kitchell, S. W. Dow, E. A. Hoover and J. I. Mullins (1994). “Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns.” J Virol 68(4): 2230-2238.
Tellier, M. C., R. Pu, D. Pollock, A. Vitsky, J. Tartaglia, E. Paoletti and J. K. Yamamoto (1998). “Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.” Aids 12(1): 11-18.
Toyosaki, T., T. Miyazawa, T. Furuya, K. Tomonaga, Y. S. Shin, M. Okita, Y. Kawaguchi, C. Kai, S. Mori and T. Mikami (1993). “Localization of the viral antigen of feline immunodeficiency virus in the lymph nodes of cats at the early stage of infection.” Archives of Virology 131(3): 335-347.
Troyer, J. L., J. Pecon-Slattery, M. E. Roelke, W. Johnson, S. VandeWoude, N. Vazquez-Salat, M. Brown, L. Frank, R. Woodroffe, C. Winterbach, H. Winterbach, G. Hemson, M. Bush, K. A. Alexander, E. Revilla and S. J. O’Brien (2005). “Seroprevalence and genomic divergence of circulating strains of feline immunodeficiency virus among Felidae and Hyaenidae species.” J Virol 79(13): 8282-8294.
Tozzini, F., D. Matteucci, P. Bandecchi, F. Baldinotti, K. H. J. Siebelink, A. Osterhaus, and M. Bendinelli. 1993. Neutralizing antibodies in cats infected with feline immunodeficiency virus. J. Clin. Microbiol. 31:1626–1629
Westman, M. E., R. Malik, E. Hall, P. A. Sheehy and J. M. Norris (2015). “Determining the feline immunodeficiency virus (FIV) status of FIV-vaccinated cats using point-of-care antibody kits.” Comp Immunol Microbiol Infect Dis 42: 43-52.
Westman, M. E., R. Malik and J. M. Norris (2019). “Diagnosing feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) infection: an update for clinicians.” Aust Vet J 97(3): 47-55.
Yamamoto, J. K., H. Hansen, E. W. Ho, T. Y. Morishita, T. Okuda, T. R. Sawa, R. M. Nakamura and N. C. Pedersen (1989). “Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission.” J Am Vet Med Assoc 194(2): 213-220.
Yamamoto, J. K., E. Sparger, E. W. Ho, P. R. Andersen, T. P. O’Connor, C. P. Mandell, L. Lowenstine, R. Munn and N. C. Pedersen (1988). “Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats.” Am J Vet Res 49(8): 1246-1258.